Alterations of membrane lipids and in gene expression of ganglioside metabolism in different brain structures in a mouse model of mucopolysaccharidosis type I (MPS I)  by Kreutz, Fernando et al.
Gene 527 (2013) 109–114
Contents lists available at SciVerse ScienceDirect
Gene
j ourna l homepage: www.e lsev ie r .com/ locate /geneAlterations of membrane lipids and in gene expression of ganglioside
metabolism in different brain structures in a mouse model of
mucopolysaccharidosis type I (MPS I)
Fernando Kreutz a,1, Fernanda dos Santos Petry b,1, Melissa Camassola c, Vanessa Schein a,
Fátima C.R. Guma a,b, Nance Beyer Nardi d, Vera Maria Treis Trindade a,b,⁎
a Programa de Pós-Graduação em Ciências Biológicas: Bioquímica – Instituto de Ciências Básica da Saúde – Universidade Federal do Rio Grande Sul, Brazil
b Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
c Programa de Pós-graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil, Canoas, RS, Brazil
d Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, BrazilAbbreviations: CNS, Central Nervous System; GAGs
high performance thin-layer chromatography; IDUA, α
MPS I, Mucopolysaccharidosis I; NANA, N-acetyl-neura
dase 1; RT-sq-PCR, Semi quantitative Polymerase Ch
chromatography.
⁎ Corresponding author at: Dep. de Bioquímica, ICBS, Uni
do Sul, Rua Ramiro Barcelos 2600 – anexo – CEP 90.035
Tel.: +55 51 3308 5550; fax: +55 51 3308 5535.
E-mail address: vmtt@ufrgs.br (V.M.T. Trindade).
1 Both authors contributed equally to this work.
0378-1119/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.gene.2013.06.002a b s t r a c ta r t i c l e i n f oArticle history:
Accepted 6 June 2013
Available online 15 June 2013
Keywords:
Mucopolysaccharidosis
Alpha-L-iduronidase
Gangliosides
GD3 synthase
GM2/GD2 synthase
Neuraminidase1Mucopolysaccharidosis I (MPS I) is a congenital disorder caused by the deﬁciency of α-L-iduronidase (IDUA),
with the accumulation of glycosaminoglycans (GAGs) in the CNS. Although GAG toxicity is not fully understood,
previous works suggest a GAG-induced alteration in neuronal membrane composition. This study is aimed to
evaluate the levels and distribution of gangliosides and cholesterol in different brain regions (cortex, cerebellum,
hippocampus and hypothalamus) in a model using IDUA knockout (KO) mice (C57BL/6). Lipids were extracted
with chloroform–methanol and then total gangliosides and cholesterol were determined, followed by ganglio-
side proﬁle analyses.While no changes in cholesterol content were observed, the results showed a tissue depen-
dent ganglioside alteration in KO mice: a total ganglioside increase in cortex and cerebellum, and a selective
presence of GM3, GM2 and GD3 gangliosides in the hippocampus and hypothalamus. To elucidate this, we
evaluated gene expression of ganglioside synthesis (GM3, GD3 and GM2/GD2 synthases) and degradation of
(Neuraminidase1) enzymes in the cerebellum and hippocampus by RT-sq-PCR. The results obtained with KO
mice showed a reduced expression of GD3 and GM2/GD2 synthases and Neuraminidase1 in cerebellum; and a
decrease in GM2/GD2 synthase and Neuraminidase1 in the hippocampus. These data suggest that the observed
ganglioside changes result from a combined effect of GAGs on ganglioside biosynthesis and degradation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Mucopolysaccharidosis (MPS) is a monogenic disease classiﬁed as
lysosomal storage disorder typically characterized by the total or par-
tial deﬁciency of an enzyme involved in the degradation pathway of
glycosaminoglycans (GAGs) (Fuller et al., 2004). Several clinical man-
ifestations of MPS have been characterized and described, and are
numerically classiﬁed from MPS I to MPS IX. Mucopolysaccharidosis
type I (MPS I) is an autosomal recessive disease caused by a genetic, glycosaminoglycans; HPTLC,
-L-iduronidase; KO, Knockout;
minic acid; Neu1, Neuramini-
ain Reaction; TLC, thin-layer
versidade Federal do Rio Grande
-003, Porto Alegre, RS, Brazil.
rights reserved.defect that codiﬁes a lysosomal hydrolase, α-L-iduronidase (IDUA)
(EC. 3.2.1.76) (Clarke et al., 1997; Freeman and Hopwood, 1992).
This enzyme degrades two particular GAGs, heparan and dermatan
sulfate. The absence or the reduced amount of this enzyme leads to
a storage of these GAGs in cells (Neufeld and Muenzer, 2001). The
phenotypes may vary considerably from a more severe (Hurler syn-
drome), to a less severe (intermediate) (Hurler–Scheie syndrome)
or else to a mild (Scheie syndrome) manifestation of the pathology.
The patients have deleterious effects in childhood and preadolescence
due to the underlying accumulation of GAGs in different organs, in-
cluding the central nervous system, reticuloendothelial system and
skeleton. In most cases the patients have progressive neurological
dysfunction. These patients are severely affected as early as in their
ﬁrst 10 years of life, and death is a very common outcome (Neufeld
and Muenzer, 2001; Zheng et al., 2003). This form of disease, as
well as its other manifestations, is very complex. It is most typically
deﬁned by storage sites of heparan and dermatan sulfate, as previous-
ly mentioned (Liu et al., 2005; Neufeld and Muenzer, 2001; Zheng et
al., 2003). Nevertheless, little is known about changes in cell dynam-
ics caused by this accumulation (Holley et al., 2011).
110 F. Kreutz et al. / Gene 527 (2013) 109–114Nowadays, a signiﬁcant lack of biomarkers is observed, whether
biochemical or molecular biology levels. These biomarkers would be
a starting point for the studies on physiopathological parameters of
the disease (Campos and Monaga, 2012). The description of these
factors would allow more thorough investigations of the possible
treatment strategies, and would also provide additional tools for the
follow-up stages of these studies and assist in the development of
post-treatment applications. In this scenario, some previously studied
factorsmight become the object of future research like the characteriza-
tion and quantiﬁcation of membrane lipid components (ganglioside
and cholesterol) in different brain structures.
Gangliosides are the most complex glycosphingolipids. They con-
tain oligosaccharides with one or more sialic acid residues, which ac-
count for their total negative charge. Gangliosides are mainly present
in the plasma membrane of cells and are highly expressed in the verte-
bral central nervous systemwhere they are involved in neural develop-
ment. They are also related to cell differentiation and proliferation and
to signal transduction. Of the several types characterized, the most
signiﬁcantly expressed gangliosides in the central nervous system are
GM1, GD1a, GD1b, and GT1b (Yu et al., 2012; Zeller and Marchase,
1992). Gangliosides GM2 and GM3 are glycosphingolipids that build
up when some lysosomal storage diseases occur, among them MPS I.
Some studies have demonstrated the accumulation of these ganglio-
sides in the total brain from the murine MPS I model (McGlynn et al.,
2004; Russell et al., 1998;Walkley, 2004) orwithGD3, in some brain re-
gions (Heinecke et al., 2011; Wilkinson et al., 2012). On another hand,
Walkey (1995) demonstrated a striking correlation between abnormal-
ly elevated levels of GM2within pyramidal neurons and the presence of
new dendritic sprouting.
This lipid accumulation can occur due to the changes on ganglio-
side biosynthesis and/or degradation processes (Fig. 1) (Tettamanti,
2004; Yu et al., 2009).
The present study analyzes the ganglioside content and proﬁle in the
cortex, cerebellum, hippocampus and hypothalamus of IDUA knockout
mice (MPS I mice) in comparison to wild type animals. This report also
describes, for the ﬁrst time, in cerebellum and hippocampus of
IDUA knockout mice, the gene expression of ganglioside synthesis
(GM3, GD3 and GM2/GD2 synthases) and ganglioside degradation
(Neuraminidase1-Neu1) enzymes (Fig. 1) by RT-sq-PCR. In addition,
the cholesterol level, an important membrane ﬂuidizer, was assessed
(Simons and Ehehalt, 2002).
2. Material and methods
2.1. Animal model
C57Bl/6 knockout mice deﬁcient for α-L-iduronidase (IDUA-KO)
represent a murine model for human MPS I. MPS I mice were derivedFig. 1. Biosynthesis and degradation pathways of a-, b-series gangliosides. Neu 1: neur-
aminidase 1.from animals kindly provided by Dr Elizabeth Neufeld (UCLA, Los
Angeles, CA, USA). The mice were produced by targeted disruption of
the murine IDUA gene (Ohmi et al., 2003). The colony was maintained
by breedingheterozygous animals, and homozygousmutantswere iden-
tiﬁed at birth by polymerase chain reaction. The animals were kept in
standard conditions and were used in the experiments at 5 months of
age (Reolon et al., 2006). All experimental procedures were in accor-
dance with the NIH Guide for Care and Use of Laboratory Animals (NIH
publication No. 85-2 3 revised 1996) and the procedures of the Brazilian
College of Laboratory Animal and were approved by the institutional re-
search ethics and animal care committee.2.2. Materials
GM3, GM2, GM1, GD3, GD1a, GD2, GD1b and GT1b gangliosides and
thiobarbituric acid were obtained from Sigma-Aldrich (Saint Louis, MO,
USA). Silica-gel 60 thin-layer chromatography (TLC) and silica-gel 60
high performance thin-layer chromatography (HPTLC) sheets were
supplied by Merck (Darmstadt, Germany).
Total RNA was extracted using the Trizol method (Invitrogen, São
Paulo, SP, Brazil). First strand cDNAwas synthesized using SuperScript®
III First-Strand Synthesis SuperMix (Invitrogen São Paulo/SP Brazil).
Quantiﬁcation of gene expression was carried out by RT-sq-PCR using
Platinum® Taq DNA Polymerase (Invitrogen, São Paulo, Brazil), dNTPs
(Ludwig Biotechnologies, Alvorada, Brazil), and primers. Speciﬁc primers
for each gene were designed using the IDT Design Software (Integrated
DNA Technologies Inc., USA).
All other chemicals and solvents used were of analytical grade.2.3. Lipid extraction
Animals were decapitated and cortex, cerebellum, hippocampus
and hypothalamus were removed, weighed and homogenized in a
2:1 mixture of chloroform:methanol (C:M, 2:1, v/v) to a 20-fold dilu-
tion of tissue mass and centrifuged at 800 ×g for 10 min. The pellet
was re-homogenized in C:M (1:2, v/v) to a 10-fold dilution of original
sample mass (Folch et al., 1957). The C:M extracts were combined
and this pool was used for the following determinations. Considering
the hippocampus and hypothalamus low mass, pools of ﬁve respec-
tive structures were used for this methodology.2.4. Ganglioside evaluation
Aliquots from the total lipid extracts were used for ganglioside de-
termination by the N-acetyl-neuraminic acid (NANA) quantiﬁcation
with the thiobarbituric acid method described by Skoza and Mohos
(1976).
Ganglioside species were analyzed by thin layer chromatography
(TLC) as a screening chromatography. Groups which presented gangli-
oside proﬁle with a noticeable alteration were again analyzed using
high performance thin layer chromatography (HPTLC) in order to con-
ﬁrm the preliminary results. TLC (cortex and cerebellum) or HPTLC
(hippocampus and hypothalamus) was performed on 10 × 10 cm
Merck plates of silica gel 60 using a developing tank described by
Nores et al. (1994). Aliquots of total lipid extracts, containing 16 nmol
of NANA suspended in 10 μL C:M (1:1), were spotted on 8 mm lanes.
HPTLC was developed, sequentially, with two mixtures of solvents,
ﬁrst C:M (4:1, v/v) and second C:M: 0.25% CaCl2 (60:36:8, v/v). The
ganglioside proﬁle was visualized with resorcinol reagent (Lake and
Goodwin, 1976; Svennerholm, 1957). Chromatographic bands were
quantiﬁed by scanning densitometry at 580 nm with a CS 9301 PC
SHIMADZU densitometer. The terminology used herein for gangliosides
was the one recommended by Svennerholm (1963).
Fig. 2. Total ganglioside contents in the different brain structures analyzed. Data are
expressed as mean ± SE for 5 animals in each group. Pools of ﬁve structures were used
to obtain triplicate data from the hippocampus and hypothalamus. KO: Knockout; WT:
Wild type. *Different fromWt, p b 0.05.
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Aliquots of total lipid extract were evaporated, suspended in
isopropanol and quantiﬁed according to an enzymatic method
(Bergmeyer, 1974) and using a commercial kit (Cholesterol Liquiform —
Labtest, Lagoa Santa, MG, Brazil).
2.6. Protein quantiﬁcation
Protein sediment obtained after lipid extraction was dissolved
with NaOH 1 N and measured by the method of Lowry et al. (1951)
using bovine serum albumin as standard.
2.7. Semi quantitative PCR (RT-sq-PCR) of GM3 synthase (EC 2.4.99.9),
GD3 synthase (EC 2.4.99.8), GM2/GD2 synthase (EC 2.4.1.92) and
Neuraminidase1 (EC 3.2.1.18) enzyme mRNA expression
Animals were decapitated and cerebellum and hippocampus were
dissected out under sterile conditions, collected in RNAse-free poly-
propylene tubes, immediately frozen in liquid nitrogen and stored
at −80 °C. Total RNA was extracted with Trizol according to
manufacturer's instructions. RNA integrity, purity and concentration
were checked by electrophoresis in 1% agarose gel and spectropho-
tometry. First strand cDNA was synthesized from 1.5 μg of total
RNA. Each cDNA pool was then aliquoted and stored at −20 °C.
Gene sequence information of GM3 synthase (NCBI reference
sequence NM_011375.2), GD3 synthase (NCBI reference sequence
NM_011374), GM2/GD2 synthase (NCBI reference sequence
NM_008080.5), and Neuraminidase1 (NCBI reference sequence
NM_010893.3) was collected from databases (www.ncbi.nlm.nih.
gov and www.ensembl.org). Speciﬁc primers for each gene were
designed using the IDT Design Software (Integrated DNA Technologies
Inc., USA) avoiding primers that could generate secondary structures
(primers and template). The primers for GM3 synthase (forward: 5′
AAT GCA CTA TGT GGA CCC TG 3′; reverse: 5′ GTT GAT GCT GTA CCT
GTC CTC 3′) were designed between exons 3 and 4; for GD3 synthase
(forward: 5′ CGA TAA TTC CAC GTA CTC CCT C 3′; reverse: 5′
TTTGGAACCGACATCTCTGG 3′) between exons 2 and 4; for GM2/GD2
synthase (forward: 5′ TCAGGATCAAGGAGCAAGTG 3′; reverse: 5′ AAG
GCTTTAGTGAGGTCAACC 3′) between exons 2 and 3 and for Neuramin-
idase1 (forward: 5′ TGC ATC CGA TGA GG GGGC CA 3′; reverse: 5′ CCA
CAG CGC CCA GGT TCA GG 3′) between exons 2 and 3. The results were
normalized using reference gene B2M (forward: 5′ ATT CAC CCC CAC
TGA GAC TG 3′, exon 2 and reverse: 5′ TGC TAT TTC TTT CTG CGT GC
3′; exon 4; NCBI reference sequence NM_009735.3). All primer se-
quences were assessed for speciﬁcity using non-redundant basic local
alignment search tools (www.ncbi.nlm.nih.gov/BLAST) and target-
speciﬁc sequence alignment programs.
Analysis of ganglioside metabolism enzyme gene expression was
carried out by RT-sq-PCR using 1× PCR Buffer, 1.5 mM MgCl2, 1 U
Platinum® Taq DNA Polymerase, 0.2 mM dNTPs, and 0.2 mM of each
transcript speciﬁc primer in a 25 ul ﬁnal reaction volume. Reactions
were conducted in a Verity thermocycler (Applied-Biosystems, USA)
according to the thermocycling conditions: 1 min at 94 °C followed by
40 cycles of 20 s at 94 °C, 20 s at a 60 °C, and 20 s at 72 °C, followed
by a ﬁnal extension step of 7 min at 72 °C. The PCR products obtained
were run in 1.0% electrophoresis agarose gel, and the PCR products
were quantiﬁed using Alpha Easy FC Software (version 6.0.0; Alpha
Innotech Corp.). All experiments were repeated at least twice.
2.8. Statistical analyses
The results are expressed as mean ± standard error for the mean
(SE). All analyses were performed using the Statistical Package for the
Social Sciences (SPSS) software in a PC-compatible computer. Student's
t-test was used to compare means between IDUA knockout and wildtype animals. Differences were considered statistically signiﬁcant if
p b 0.05.3. Results
3.1. Ganglioside analysis
Total ganglioside contents were statistically higher in cortex and
cerebellum of MPS I animals than in wild type mice (Fig. 2). On the
other hand, in the hippocampus and hypothalamus of IDUA knockout
mice, the amount of gangliosides was similar to that observed in the
same structures of wild type animals.
The four main central nervous system gangliosides (GM1, GD1a,
GD1b and GT1b) were detected in the cerebral structures studied.
The proﬁles of the different ganglioside species from wild-type and
MPS I animals, obtained by using TLC, were apparently unaffected in
cortex and cerebellum. Relating this observation to total ganglioside
contents, it could indicate an increase of the detected ganglioside spe-
cies in cortex and cerebellum of MPS I mice (Table 1). However, espe-
cially GM3, GM2 and GD3 gangliosides have noticeable contents in
hippocampus and hypothalamus of MPS I animals in comparison to
wild-type (Table 1). Besides these, other minor gangliosides were also
found in the hippocampus (GX) and hypothalamus (GX and GQ1b).3.2. Cholesterol quantiﬁcation
Cholesterol level from brain structures was quantiﬁed as described
in theMaterials andmethods section. Therewas no statistical difference
between MPS I and wild type animals for this lipid parameter (Fig. 3).3.3. Relative expressions of ganglioside metabolism genes
As cortex and cerebellum like hippocampus and hypothalamus
presented, respectively, similar results for ganglioside concentration
and proﬁle we decided to evaluate the relative expressions of gangli-
oside metabolism genes only in cerebellum and hippocampus. In both
regions GM3 synthase expression was not altered when comparing
KO and Wt animals. On the other hand, in cerebellum of KO mice, a
reduction in gene expressions of GD3 synthase (43.2%), GM2/GD2
synthase (34.2%) and Neuraminidase1 (58.1%) was observed in com-
parison to their expressions inWt animals (Fig. 4). However, in the hip-
pocampus, there was a decrease in gene expression only for GM2/GD2
synthase (22.3%) and Neuraminidase1 (46.9%) enzymes in KO mice
compared to the expressions in Wt animals, respectively (Fig. 4).
Table 1
Percentage distribution of gangliosides.
Cortex Cerebellum Hippocampus Hypothalamus
KO Wt KO Wt KO Wt KO Wt
GM3 – – – – 3.1 (±0.3) – 10.2 (±2.0) –
GM2 – – – – 1.3 (±0.1) – 3.5 (±1.0) –
GM1 23.0 (±1.8) 24.8 (±1.9) 12.9 (±0.9) 13.6 (±0.7) 13.2 (±1.8) 15.8 (±2.1) 12.4 (±0.9) 13.7 (±0.8)
GD3 – – – – 2.2 (±0.2) – ⁎4.1 (±0.6) 2.1 (±0.5)
GD1a 41.8 (±1.9) 41.9 (±1.6) 28.6 (±2.3) 34.5 (±1.2) 36.9 (±2.7) 39.1 (±4.3) 23.3 (±2.2) 30.4(±2.8)
GX⁎ – – – – 4.3 (±0.4) 4.1 (±0.4) 8.1 (±0.8) 7.4 (±0.9)
GD1b 15.9 (±0.7) 16.9 (±0.6) 19.7 (±1.7) 16.3 (±2.3) 8.6 (±1.3) 7.3 (±1.9) 8.3 (±0.9) 11.9 (±1.2)
GT1b 19.3 (±3.7) 16.6 (±0.9) 38.8 (±2.0) 35.6 (±3.0) 30.4 (±0.8) 32.7 (±4.7) 22.6 (±0.9) 25.8 (±0.8)
GQ1b – – – – – – 7.5 (±1.0) 8.7 (±0.7)
Values represent percentage mean ± SE.
GX⁎ = could be GT1a or GD2 or LD1.
⁎ Different from Wt, p b 0.05.
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Mucopolysaccharidosis type I is a lysosomal storage disease aris-
ing from a lack of activity of the α-L-iduronidase enzyme. This en-
zyme breaks down glycosaminoglycans (GAGs) heparan sulfate and
dermatan sulfate. There is an involvement of multiple organs and
some symptoms include growth delay, hepatosplenomegaly, coarse
facial features, excessive urinary GAGs, skeletal abnormalities and
neurological deﬁcits (Neufeld and Muenzer, 2001).
Because MPS I is a degenerative disorder with a progressive accu-
mulation of heparan sulfate and dermatan sulfate, it has become a key
object for the analysis of neurochemical parameters. Considering the
important roles played by membrane lipids in central nervous system
development, and that some studies have sometimes reported alter-
ations in total ganglioside content and others demonstrated the exis-
tence of GM3, GM2 and GD3 storage sites in patients and MPS I
models, as well as of cholesterol secondary storage (Abraham et al.,
1969; Heinecke et al., 2011; Ikeno et al., 1982; Ledeen et al., 1965;
McGlynn et al., 2004; Russell et al., 1998; Walkley, 2004; Wilkinson
et al., 2012), detailed investigations on these lipids, mainly on gangli-
oside composition and metabolism, are needed to elucidate issues
related to the murine model.
The present study reveals an increase in total ganglioside content
in the cortex and cerebellum of MPS I mice, while in the hippocampus
and hypothalamus of IDUA knockout mice, the amount of gangliosides
was similar to that observed in the same structures ofwild type animals.
It can be found in the literature that total brain ganglioside sialic acid
content in patients is increased in some reports and decreased or
unchanged in others (Abraham et al., 1969; Constantopoulos andFig. 3. Cholesterol levels in the different brain structures analyzed. Data are expressed asmean
from the hippocampus and hypothalamus. KO: Knockout; Wt: Wild type. *Different fromWt,Dekaban, 1978; Ikeno et al., 1982; Wherret, 1968). Our values for cere-
bellum are different from those determined by Heinecke et al. (2011),
perhaps due to distinct evaluation procedures. Nevertheless, our data
are the ﬁrst report for hippocampus and hypothalamus.
The four main gangliosides present in the brain (GM1, GD1a, GD1b,
and GT1b) were detected in the mouse cerebral regions studied. In ce-
rebral cortex and cerebellum, the proﬁles of ganglioside species from
IDUA knockout and wild-type groups were apparently unaffected.
These observations, mainly for cerebellum, do not agree with that
previously reported (Heinecke et al., 2011), probably due to different
methodological analyses. However, GM3, GM2 and GD3 gangliosides
have noticeable contents in hippocampus and hypothalamus of MPS I
animals. Besides these, otherminor gangliosides were found in the hip-
pocampus (GX) and hypothalamus (GDx and GQ1b). Ganglioside GDx
could be GT1a or LD1 as detected in mouse cerebellum (Heinecke et
al., 2011; Ohsawa, 1989; Seyfried et al., 1978). The presence or the ele-
vation of GD3, respectively in hippocampus or in hypothalamus from
MPS I animals could suggest neurodegeneration since this ganglioside
is enriched in reactive astrocytes and is considered a good parameter
for neurodegeneration (Seyfried and Yu, 1985). Wilkinson et al. (2012)
reported a detailed study comparing the brain of mouse models of
mucopolysaccharidosis types I, IIIA and IIIB at 4 and 9 months of age.
They showed interesting data about neuroinﬂammation, astrocytosis,
microgliosis and synaptic disorganization. Besides these, they detected
the GM2 ganglioside immunoreactivity in cortex slices of MPS mice and
that it has an intense vesicular pattern in layers II/III and V/VI with less
staining in layer IV and negligible in wild-type. The authors did not
observe signiﬁcant differences between the MPS genotypes and no
overall time effect for GM2 immunoreactivity. Intense staining for± SE for 5 animals in each group. Pools of ﬁve structureswere used to obtain triplicate data
p b 0.05.
Fig. 4. Relative expressions of ganglioside metabolism genes. (A) Representative image of RT-sq-PCR gels; (B) quantiﬁcation of the PCR bands. Data represent mean ± SE. n = 4.
KO: Knockout, Wt: Wild type. *Different from Wt, p b 0.05.
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type brains such as amygdala, lateral septal nucleus, stria terminalis,
preoptic area, hypothalamic areas and pyramidal cells of hippocampus.
In addition, Walkley (1995) observed an elevated immunoreactivity
for GM2 ganglioside in pyramidal neurons which showed an ectopic
dendritogenesis. Sohn et al. (2006) demonstrated that an increase in
GM3 might be directly associated with oxidative glutamate toxicity. In a
previous study it has been shown that glutamate uptake and the number
of glutamate receptors were reduced inMPS I animals (Camassola, 2008)
Nevertheless, generally speaking, this increase in GM3may be caused by
the inhibition of the enzymes responsible for glycosphingolipid degrada-
tion, induced by GAGs stored in cells (McGlynn et al., 2004). As GM3 ex-
pression occurs predominantly during embryo development (Yu et al.,
2009, 2012), accumulation of this ganglioside in MPS I brain patients
could be involved in their slow neural development (Ikeno et al., 1982).
It is also known that glycosphingolipids are involved in electric ef-
fects and in the concentration of ions like Ca+2, as well as in the for-
mation of membrane rafts, a feature that has proved its importance in
the proper function of CNS signaling routes (Furukawa et al., 2011;
Harder and Simons, 1999). Thus, changes in glycosphingolipid compo-
sition and amount may inﬂuence these processes (Harder and Simons,
1999; Simons and Ehehalt, 2002; Yu et al., 2012). Theﬁndings described
in the present study for the brain structures of MPS I animals may ex-
plain behavioral data already obtained for these animals, as described
by Reolon et al. (2006) and improved by gene therapy as reported by
Baldo et al. (2013).
In this report, the quantiﬁcation of cholesterol levels in the different
brain structures did not show any differences between healthy and
MPS I animals. Considering that the characteristics of the MPS I tend to
vary considerably with age (Russell et al., 1998; Zheng et al., 2003),
other researchers (Heinecke et al., 2011) evaluated the total lipid distri-
bution in the whole brain and cerebellum of MPS IH and control mice at
6 months and at 12 months of age. No other signiﬁcant lipid differences
(cholesterol, phospholipids) were found in either whole brain or in the
cerebellum at either age. However, the content of total sialic acid and
levels of gangliosides GM3, GM2, and GD3 were higher in the whole
brains of mice than in control mice at 12 months of age. On the other
hand, an immunohistochemical evaluation conducted by McGlynn et
al. (2004), demonstrated that cholesterol storage sites were found only
there where GM2 and GM3 were accumulated, but in separate vesi-
cles within affected neurons from MPS I mice. This Important obser-
vation indicates that ganglioside storage was not simply due to the
GAG-inhibition of speciﬁc lysosomal hydrolases, but suggests that
other mechanisms, such as ganglioside synthesis and/or trafﬁcking
alterations could be responsible for their increase in MPS disorders.Aiming to study the changes in the content and proﬁle of the gangli-
osides observed in the present report, the gene expression of enzymes in-
volved in ganglioside metabolism was investigated using the technique
of RT-sq-PCR. For these analyses the cerebellum and the hippocampus
were used. They have shown, respectively, as cortex and hypothalamus,
an increase in the total ganglioside content and accumulation of GM3,
GM2 andGD3 in KO animals for the IDUA gene. Ganglioside biosynthesis,
in turn, was evaluated by the gene expression of 3 enzymes: GM3 and
GD3 synthases involved in the synthesis of simple gangliosides (GM3
and GD3) which are precursors of complex gangliosides; and GM2/GD2
synthase, a common enzyme controlling the synthesis of complex gangli-
osides along different pathways (Maccioni et al., 1999; Yu et al., 2012).
However, as ganglioside content is determinedby a ratio between its syn-
thesis and degradation, gene expression of Neuraminidase1, a key en-
zyme of lysosomal degradation of these glycosphingolipids, was also
assessed (Miyagi and Yamaguchi, 2012; Tettamanti, 2004).
In the cerebellum, a decrease in the gene expression of three en-
zymes tested in KO animals was observed (GD3 synthase, GM2/GD2
synthase and Neuraminidase1) compared respectively to the expres-
sions in wild type mice. The reduction of synthase expressions was
smaller than Neuraminidase 1 suggesting that anabolic route could be
favored and so explaining the increase in ganglioside concentration in
KO mouse cerebellum. In the hippocampus, there was a decrease in
gene expression for GM2/GD2 synthase and Neuraminidase1 enzymes
in KO mice compared, respectively, to the expressions in Wt animals.
These results are in agreement with the accumulation of GM3 and
GD3 detected in this structure. However, at the moment there is not
an explanation for GM2 accumulation.
Studies in the literature reported that an increase in intracellular
GAGs, which occurs in MPS I, reduces neuraminidase activity in the
lysosome (Walkley, 2004) and modiﬁes glycosphingolipid synthesis
in the Golgi complex (Campos and Monaga, 2012). This alteration
could be associated to the impairment of activation of some intracel-
lular transduction pathways linked to glycosyltransferase expression
(Campos and Monaga, 2012; Maccioni et al., 1999; Morrison, 2012;
Ngamukote et al., 2007). In addition, GAG accumulation alter the traf-
ﬁcking and/or recycling of gangliosides, and lipid raft composition
and, therefore, damaging neuronal function (Campos and Monaga,
2012; Daniotti and Iglesias-Bartolomé, 2011; Walkley, 2004).
Taking together, the data from this report conﬁrm, in part, previous
suggestions that ganglioside changes are due to a combined effect on
ganglioside biosynthesis and degradation. Considering the importance
of gangliosides in cell biology and in the GM3 pro-apoptotic role
(Sohn et al., 2006), these ﬁndings may be related to the neurological
dysfunction of MPS I. The results obtained in the present study indicate
114 F. Kreutz et al. / Gene 527 (2013) 109–114that ganglioside content and proﬁle may be efﬁciently employed as
follow-up parameters in MPS I models, during and after preclinical
tests of gene therapy, cellular therapy, and enzyme replacement thera-
py (Baldo et al., 2013; Camassola et al., 2005; Zheng et al., 2003). Apart
from this, ganglioside storage sites are also important in the investiga-
tions of new mechanisms of neuronal dysfunction in MPS I individuals
(Campos and Monaga, 2012; Wilkinson et al., 2012).
5. Conclusions
The reported data add a new aspect to the ganglioside accumulation
in patients and MPS I models. The alteration in the metabolism of gan-
gliosides is not only given by the direct action of GAGs on the enzymes
involved in their degradation, but also by the GAGs' inﬂuence on the
gene expression of Neuraminidase 1 (degradation) and GD3 synthase,
and GM2/GD2 synthase (biosynthesis).
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